Engineering switchable and programmable universal CARs for CAR T therapy.

Area of Science:

• Immunotherapy
• Oncology
• Biotechnology

Background:

• Traditional chimeric antigen receptor (CAR) T cells have a fixed design, targeting a single antigen epitope, limiting clinical use and increasing costs.
• This rigidity necessitates re-engineering CAR T cells for different targets, hindering broader application and manufacturing efficiency.

Purpose of the Study:

• To introduce and explore the potential of a modular universal CAR (UniCAR) T cell platform.
• To highlight the advantages of UniCAR in terms of versatility, re-programmability, and potential cost reduction in CAR T cell therapy.

Main Methods:

• Engineering CAR T cells with a modular design, separating the antigen recognition domain from the signaling domain.
• Utilizing a two-component system: a signaling module and a switchable module with an antigen-binding domain.
• Development of various switchable modular designs, including dimerizing platforms and neo-epitope tagging.

Main Results:

• The UniCAR platform enables switching or re-directing target antigens without re-engineering CAR T cells.
• Switch molecules act as a synapse between CAR T cells and tumor cells, demonstrating high versatility.
• Potential for significantly lowering the cost of CAR T cell therapy due to its re-programmable nature.

Conclusions:

• The UniCAR platform presents a highly versatile and potentially cost-effective approach to CAR T cell therapy.
• Challenges include potential immunogenicity from exogenous epitopes in switching molecules and complex regulatory considerations for these novel agents.